SEMAGLUTIDE

Semaglutide is an incretin mimetic. Also referred to as a glucagon-like peptide-1 (GLP-1) agonist, Semaglutide was developed to improve glycemic control in T2DM as an adjunct to diet and exercise. Semaglutide enhances the growth of beta cells in the pancreas where insulin is produced. It also delays gastric emptying by reducing glucagon secretion, reducing appetite, improving control of eating, and reducing food cravings. As shown in research studies, Semaglutide reduces HbA1c levels and moderates weight loss, which leads to a significant reduction of major adverse cardiac events.